8-甲基癸酸 | 5601-60-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 8-甲基癸酸
• 中文别名: 8-甲基葵酸
• 英文名称: 8-methyldecanoic acid
• 英文别名: (±)-8-methyldecanoic acid
• CAS: 5601-60-5
• 化学式: C₁₁H₂₂O₂
• mdl: MFCD02258676
• 分子量: 186.294
• InChiKey: WGKCPRZDCLXOIQ-UHFFFAOYSA-N

物化性质

• 沸点：
  278.57°C (estimate)
• 密度：
  0.8978 (rough estimate)
• LogP：
  4.108 (est)
• 稳定性/保质期：
  存在于香料烟烟叶中。

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  13
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.909
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332
• 储存条件：
  存储条件：2-8°C，干燥。

制备方法与用途

合成制备方法

1. 烟草：OR，26。

反应信息

• 作为反应物：
  描述：

  8-甲基癸酸 在 immobilised Candida rugosa Lipase 1-十六烷醇 、 sodium sulfate 、 氢氧化钾 作用下， 以 环己烷 、 1,4-二氧六环 、 甲醇 为溶剂， 反应 5.0h， 生成 (S)-8-甲基癸酸
  参考文献：
  名称：

  Do enzymes recognise remotely located stereocentres? Highly enantioselective Candida rugosa lipase-catalysed esterification of the 2- to 8-methyldecanoic acids

  摘要：

  Several racemic methyl decanoic acids have been synthesised and Successfully resolved in esterification with 1-hexadecanol at a(w)=0.8 in cyclohexane using immobilised Candida rugosa lipase (CRL) as the catalyst. The enantiomeric ratios (E=2.8-68) obtained were surprisingly high even when the methyl group was as remotely located as in 8-methyldecanoic acid (E=25). Interestingly, the lipase shows enantiopreference for the S-enantiomer when the methyl group is located on even numbered carbons i.e. for the 2-,4-,6- and 8-methyldecanoic acids and to the R-enantiomer when the methyl group is located on uneven numbered carbons i.e. for the 3-,5- and 7-methyldecanoic acids. (C) 2002 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0957-4166(02)00172-6
• 作为产物：
  描述：

  2-甲基丁酰氯 在 氢氧化钾 、 三乙醇胺 、 一水合肼 作用下， 反应 2.0h， 生成 8-甲基癸酸
  参考文献：
  名称：

  Huenig,S.; Salzwedel,M., Chemische Berichte, 1966, vol. 99, p. 823 - 842

  摘要：

  DOI：

文献信息

• [EN] LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES ORIENTANT VERS LE SYSTÈME LYMPHATIQUE
  申请人：ARIYA THERAPEUTICS INC

  公开号：WO2019046491A1

  公开（公告）日：2019-03-07

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，其制药组合物，制备这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所提供的脂质前药或其制药组合物。
• [EN] LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF<br/>[FR] PROMÉDICAMENTS LIPIDIQUES DE NEUROSTÉROÏDES DE PRÉGNANE ET LEURS UTILISATIONS
  申请人：PURETECH HEALTH LLC

  公开号：WO2020028787A1

  公开（公告）日：2020-02-06

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，以及其制药组合物、生产这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所述的脂质前药或其制药组合物。
• Total Synthesis of A54145 Factor D
  作者：Braden Kralt、Ryan Moreira、Michael Palmer、Scott D. Taylor

  DOI：10.1021/acs.joc.9b01938

  日期：2019.9.20

  An efficient total synthesis of A54145 factor D (A5D), a member of the A54145 family of cyclic lipodepsipeptide antibiotics, is reported. The peptide was constructed by attaching the peptide to the 2′-chlorotrityl polystyrene resin via Sar5 and developing conditions that avoided diketopiperazine formation upon subsequent elaboration using 9-fluorenylmethoxycarbonyl solid-phase peptide synthesis. This

  据报道，A54145因子D（A5D）是环状脂肽肽抗生素A54145家族的成员，可以有效地进行全合成。通过经由Sar5将肽连接至2'-氯三苯甲基聚苯乙烯树脂并开发避免在随后使用9-芴基甲氧基羰基固相肽合成进行精制后形成二酮哌嗪的条件，来构建肽。该途径允许关键的deps键的容易形成。将支链的无环前体从树脂上环化，然后整体脱保护以获得A5D。与其他人的最新研究一致，我们发现MeOAsp残基具有2 S，3 R构型。我们还确定了前isoiso中的立体中心的配置-十一烷酰脂质尾巴不影响生物活性。
• [EN] LIPID PRODRUGS OF NEUROSTEROIDS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES DE NEUROSTÉROÏDES
  申请人：PURETECH LYT INC

  公开号：WO2021159021A1

  公开（公告）日：2021-08-12

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统导向的脂质前药、其药物组合物、制备此类前药和组合物的方法，以及提高包含在脂质前药中的治疗剂的生物利用度或其他特性的方法。本发明还提供了治疗如本文所述的疾病、紊乱或状况的方法，包括向有需要的患者施用所述的脂质前药或其药物组合物。
• Antiinfective Lipopeptides
  申请人：Alexander Christopher Dylan

  公开号：US20080051326A1

  公开（公告）日：2008-02-28

  The present invention relates to novel depsipeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel depsipeptide compounds and intermediates used in producing these compounds.

  本发明涉及新型脱氨肽类化合物。该发明还涉及这些化合物的药物组合物以及将这些化合物用作抗菌化合物的方法。该发明还涉及生产这些新型脱氨肽类化合物以及用于生产这些化合物的中间体的方法。